Jump to content

Dapagliflozin: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

2 September 2024

23 July 2024

16 July 2024

19 June 2024

20 May 2024

12 May 2024

11 May 2024

10 May 2024

29 April 2024

20 April 2024

19 April 2024

  • curprev 04:0804:08, 19 April 2024Shelbyorch talk contribs 52,538 bytes −814 Fixed numerous repeats of the same information multiple times in the medical uses and adverse events section. Fixed many wording issues and grammatical errors. Re-organized some information to make more logical sense. Did not add any new information. undo Tag: Visual edit

1 April 2024

2 March 2024

27 February 2024

13 February 2024

  • curprev 14:2314:23, 13 February 2024Pol098 talk contribs 52,958 bytes +323 It reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion . undo

31 January 2024

25 January 2024

10 January 2024

9 January 2024

4 January 2024

24 December 2023

20 December 2023

12 December 2023

2 December 2023

1 December 2023

5 November 2023

26 August 2023

21 August 2023

17 August 2023

13 August 2023

18 June 2023

17 June 2023

10 June 2023

7 June 2023

4 June 2023

19 May 2023

14 May 2023

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)